SES and Intelsat Propose Joint Use of C-band by Satellite and Terrestrial Mobile Operators in the U.S.
Leading satellite companies SES S.A. (Euronext Paris and Luxembourg Stock Exchange: SESG) and Intelsat S.A. (NYSE: I) today announced alignment on a proposal to the United States Federal Communications Commission (FCC) which seeks to protect the wide array of established satellite services in the 3700-4200 MHz C-band downlink spectrum while opening a specified portion of that spectrum for terrestrial mobile use.
The joint proposal, which was developed in response to the unique U.S. telecommunications environment, aims to protect the quality and reliability of the extensive services provided by satellite operators in C-band to U.S. broadcasters, media and data companies. The proposal ensures the continued seamless distribution of video and audio programming to more than 100 million U.S. households, and the reliable provision of critical data connectivity in rural areas and emergency situations, as well as services delivered to the U.S. government.
The proposal, which builds on an innovative model first put forward to the FCC by Intelsat and Intel Corporation in October 2017, sets a commercial and technical framework that would enable wireless operators to quickly access approximately 100 MHz of nationwide C-band downlink spectrum in the U.S., speeding the deployment of next generation 5G services.
The proposal specifies the creation of a consortium, which would be open to all C-band operators providing service to all or a portion of the lower 48 United States pursuant to FCC-issued licenses or grants of market access. The consortium would oversee the governance of the initiative, define and implement the methodology for spectrum clearance, and serve as the sole interface for market-based transactions with parties interested in deploying terrestrial mobile services in specific portions of the C-band. SES and Intelsat have begun briefing the FCC on this proposal.
Karim Michel Sabbagh, President and CEO of SES, said, “The C-band is and remains a critical component of the U.S. network architecture. Space and ground segment operators have invested billions of dollars in U.S. C-band networks and connectivity and generate important value out of it. It is therefore our duty and mission to protect the C-band in the U.S. from any form of disruption and preserve its use. The C-band satellite consortium is to be set up to ensure that the expansion of the C-band ecosystem in the U.S. will protect the interests of hundreds of established services and millions of American end-users, while at the same time paving the way for the creation of next generation 5G terrestrial services.”
Peter Pitsch, Associate General Counsel, Intel, said, “Intel's goal remains to facilitate timely access to high quality terrestrial 5G services. We welcome the announcement of the alignment of Intelsat and SES on significant details of the proposal, and plan to continue to support this market-based approach, which we believe paves the way for the accelerated deployment of 5G in the U.S.”
Intelsat CEO Stephen Spengler said, “Our priority continues to be creating a framework that provides certainty and protects the quality and reliability of the services we provide to our media, network services and government customers. Our proposed market-based solution provides a speedy resolution to the U.S. objective of accelerating deployment of 5G services. With Intelsat and SES now in agreement on major tenets of the framework and with the support of Intel, we are confident in our ability to implement this proposal quickly and efficiently, ultimately to the benefit of American consumers and the U.S. economy.”
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
Follow us on:
Intelsat S.A. (NYSE: I) operates the world’s first Globalized Network, delivering high-quality, cost-effective video and broadband services anywhere in the world. Intelsat’s Globalized Network combines the world’s largest satellite backbone with terrestrial infrastructure, managed services and an open, interoperable architecture to enable customers to drive revenue and reach through a new generation of network services. Thousands of organizations serving billions of people worldwide rely on Intelsat to provide ubiquitous broadband connectivity, multi-format video broadcasting, secure satellite communications and seamless mobility services. The end result is an entirely new world, one that allows us to envision the impossible, connect without boundaries and transform the ways in which we live. For more information, visit www.intelsat.com.
Markus Payer, +352 710 725 500
Corporate Communications & PR
Dianne VanBeber, +1 703-559-7406
Vice President, Investor Relations
Lisa Malloy, +1 202-270-7600
Senior Director, Government Relations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Open Fiber Powers Its Optical Network With SM Optics WDM ROADM22.10.2018 07:00 | Pressemelding
Open Fiber a national wholesales operator awards SM Optics, part of SIAE MICROELETTRONICA group a contract to supply and deploy WSS-free WDM ROADM technology extending fibre connectivity from their fibre backbone to metro/regional sites. The new network transports the FTTH (fibre-to-the-home) and FWA (Fixed-wireless-access) aggregated traffic, delivering ultra-broadband service to houses and local businesses. Open Fiber mission is to build a nationwide fiber network, bringing fibre connectivity to the vast majority of households and enterprises in the country, with a target of almost 19 million property units. This optical access infrastructure will enable operators delivering next generation services from FTTH broadband network for data, gaming, video streaming and mobile connectivity to 5G and IoT. SM Optics optical transport solution offers unprecedented flexibility in the smallest footprint, successfully meeting the challenge of limited space deployment and low power consumption. F
Zscaler Extends Cloud DLP Service with Inline Exact Data Match for Massive Data Sets Covering Users Globally22.10.2018 06:30 | Pressemelding
Zenith Live Europe – Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced inline Exact Data Match (EDM) with native SSL inspection as part of its advanced Cloud Data Loss Prevention (DLP) service. The inline EDM capability extends the Zscaler™ cloud platform to protect against the loss of sensitive information across all users and branches with more precision while reducing the number of false positives to near zero. This service is provided in the Zscaler cloud, providing the capacity of one billion data points per customer across 100 data centers globally. Traditional DLP appliances that sit in the data center are expensive and resource-intensive, and their protection can be subpar, often failing to alert an organization until after data has been compromised. Zscaler’s inline EDM with native SSL inspection blocks sensitive information before it leaves the network. In the first half of 2018, the Zscaler cloud platform blocked an average of 800,000 SSL-encrypted tr
Vivior Chairman Receives Award for Outstanding Contributions to Refractive Surgery22.10.2018 06:00 | Pressemelding
Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181021005012/en/ Michael Mrochen, PhD Chairman of the Board of Directors Vivior AG (Photo: Business Wire) The International Society of Refractive Surgery (ISRS), a partner of the American Academy of Ophthalmology, is the leading worldwide organization for refractive surgeons. Each year, ISRS awards members for their special contributions to the ISRS, as well as their dedication to the field. The Casebeer Award recognizes an individual for his or her outstanding contributions to refractive surgery through nontraditional research and development activities (https://www.isrs.org/about-isrs/awards). Michael Mrochen is internationally known for his pioneering work on corneal laser surgery, corneal cross linking, ocular biometry and corn
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis22.10.2018 05:00 | Pressemelding
Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. At week 52, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** compared to patients receiving placebo (46.2% vs. 14.3%; p<0.001). A similar rate of clinical remission was observed in the vedolizumab IV reference arm (42.6%). These results were presented at the 2018 United European Gastroenterology (UEG) Week congress in Vienna, Austria. “The VISIBLE 1 results highlight that the investigational subcutaneous formulation of vedolizumab helped patients with moderat
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in